Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Frequently Asked Questions About Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
How can investors keep track of Theravance Biopharma's performance?
Investors can keep track of Theravance Biopharma's performance by following the company’s financial reports, press releases, and news updates available on its investor relations website. The company also participates in industry conferences, providing insights into its strategic goals and pipeline developments.
How does Theravance Biopharma ensure compliance with regulations?
Theravance Biopharma adheres to strict regulatory guidelines set by the U.S. Food and Drug Administration (FDA) and international agencies for drug development and commercialization. This includes conducting comprehensive clinical trials, maintaining good manufacturing practices, and ensuring that all products meet the required safety and efficacy standards.
How does Theravance Biopharma promote diversity and inclusion?
Theravance Biopharma promotes diversity and inclusion by fostering an inclusive workplace culture that values diverse perspectives and backgrounds. The company actively engages in initiatives aimed at increasing diversity in its workforce and supporting equitable opportunities within its organizational structure and community involvement.
How does Theravance Biopharma utilize technology in its operations?
Theravance Biopharma utilizes advanced technology platforms to enhance its drug discovery and development processes. These platforms include proprietary drug design technologies, such as its Dual-Action Mechanism of Action (DAMAC) platform, which helps to optimize therapeutic candidates for efficacy and safety.
Is Theravance Biopharma a public company?
Yes, Theravance Biopharma, Inc. is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol TBPH. This status allows the company to raise capital and increase its visibility in the biopharmaceutical sector.
What are some challenges Theravance Biopharma faces?
Some of the challenges faced by Theravance Biopharma include navigating the complexities of drug development, competitive pressures from other biotech firms, and the need for regulatory approval for new therapies. Additionally, the company must effectively manage its resources and funding to sustain its research and development efforts.
What does Theravance Biopharma, Inc. do?
Theravance Biopharma, Inc. is a biopharmaceutical company based in the United States that focuses on the discovery, development, and commercialization of innovative medicines primarily for respiratory diseases and other serious conditions. Leveraging its proprietary technology platforms, the company aims to develop treatments that can improve patients' quality of life.
What impact has the COVID-19 pandemic had on Theravance Biopharma?
The COVID-19 pandemic has had both challenges and opportunities for Theravance Biopharma. The company participated in the development of treatments for COVID-19, which raised its profile in the biopharma sector. However, it also faced challenges in clinical trials and operational adjustments due to pandemic-related restrictions.
What is the business model of Theravance Biopharma?
Theravance Biopharma operates on a business model that includes both developing its own therapeutic candidates and forming collaborations with other pharma companies to leverage its research capabilities. The company seeks to either commercialize its products directly or partner with others for successful market introduction.
What is the future outlook for Theravance Biopharma?
The future outlook for Theravance Biopharma is cautiously optimistic, driven by its innovative pipeline and commitment to addressing unmet medical needs. The company aims to progress its clinical candidates through the development phases, potentially leading to new product approvals and partnerships that can drive growth.
What is the mission of Theravance Biopharma?
The mission of Theravance Biopharma is to discover, develop, and deliver innovative medicines that can improve the lives of patients with serious diseases. The company is committed to addressing unmet medical needs and advancing healthcare through scientific excellence and innovation.
What is Theravance Biopharma's approach to sustainability?
Theravance Biopharma is committed to sustainability and ethical practices in its operations. The company focuses on responsible sourcing, reducing its environmental footprint, and engaging in corporate social responsibility initiatives that contribute to the well-being of its employees, stakeholders, and the communities it serves.
What is Theravance Biopharma's most notable product?
One of Theravance Biopharma's most notable products is Veklury® (remdesivir), which is an antiviral medication previously co-developed with Gilead Sciences. Initially focused on the treatment of SARS-CoV-2, it has gained attention for its efficacy in treating COVID-19.
What pipeline candidates does Theravance Biopharma have?
Theravance Biopharma has a diverse pipeline of product candidates in various stages of clinical development, focusing on novel therapies. This includes candidates aimed at treating conditions like COPD, asthma, and other chronic inflammatory diseases and includes both inhaled and systemic formulations.
What recent developments has Theravance Biopharma accomplished?
Theravance Biopharma has achieved several milestones recently, including positive clinical trial results for its investigational therapies and strategic partnerships with other pharmaceutical companies. The company continues to advance its pipeline toward regulatory submission and market launch.
What therapeutic areas does Theravance Biopharma focus on?
Theravance Biopharma primarily focuses on respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, as well as other serious conditions. The company aims to develop innovative therapies that meet significant unmet medical needs in these areas.
When was Theravance Biopharma, Inc. founded?
Theravance Biopharma, Inc. was founded in 2013 as a spin-off from Theravance, Inc. The company was created with the objective of focusing on advancing its biopharmaceutical pipeline, particularly in the field of respiratory diseases and other unmet medical needs.
Where is Theravance Biopharma, Inc. located?
The headquarters of Theravance Biopharma, Inc. is located in South San Francisco, California. The proximity to major biotech hubs allows the company to engage effectively with academic institutions, research organizations, and other biotech firms.
Who are the current executives at Theravance Biopharma?
As of the latest updates, Theravance Biopharma is led by its Chief Executive Officer, Rick E Winningham, along with a seasoned management team and a board of directors with extensive experience in the pharmaceutical and biopharmaceutical industries.
Who are Theravance Biopharma's main competitors?
Theravance Biopharma competes with a range of other biopharmaceutical companies focused on respiratory therapies, including but not limited to large pharmaceutical firms and specialized biotech companies. Competition in this niche market is driven by innovation, efficacy, and patient outcomes.
What is the current price of Theravance Biopharma, Inc. - Ordinary Shares?
The current price of Theravance Biopharma, Inc. - Ordinary Shares is 15.12
When was Theravance Biopharma, Inc. - Ordinary Shares last traded?
The last trade of Theravance Biopharma, Inc. - Ordinary Shares was at 3:11 pm EDT on March 27th, 2026
What is the market capitalization of Theravance Biopharma, Inc. - Ordinary Shares?
The market capitalization of Theravance Biopharma, Inc. - Ordinary Shares is 748.00M
How many shares of Theravance Biopharma, Inc. - Ordinary Shares are outstanding?
Theravance Biopharma, Inc. - Ordinary Shares has 49.47M shares outstanding.